BCG, OK-432, SPG or PS-K, either of which is now considered to be an effective drug for cancer immunotherapy, has been used together with radiotherapy or operation in patients with head and neck cancer in our clinic since 1973. The clinical results so far obtained are summerized as follows.
The local and systemic administration of BCG was done in our clinic. Especially in patients with cancer of maxilla treated with local application, most excellent results were obtained, showing 2-years survival rate of 86.7% (13/15).
OK-432 of 10 KE a time was locally applied to 7 cases of maxillary cancer. As compared with BCG, the local reaction was relatively weak but no side effect was noted. At present, 6 out of 7 cases are surviving over 1 year without recurrence.
SPG was administered 5-20mg a time to 25 patients with head and neck cancer. PHA skin reaction was stimulated and an increase of T cells in the peripheral blood counted more than 1000/mm3 was noted in 47.1% of these patients.
PS-K was administered to 12 cases at the same time with radiotherapy. It was noted by the decrease of T cells in the peripheral blood due to radiotherapy were prohibited as compared with 12 control cases in which radiotherapy was singly performed.
